Please login to the form below

Perjeta

This page shows the latest Perjeta news and features for those working in and with pharma, biotech and healthcare.

Ocrevus surge keeps Roche smiling in Q3

However, the performance of Ocrevus and other drugs such as HER2 breast cancer therapy Perjeta (pertuzumab) and lung cancer therapy Alecensa (alectinib) – plus a strong showing in Asia-Pacific markets led

Latest news

Roche preps new Kadcyla filings after phase 3 trial win

Neoadjuvant therapy is given with the intention of achieving a cure for patients with early-stage cancer, and Herceptin and follow-up HER2 drug Perjeta (pertuzumab) have been approved for this ... With Herceptin and follow-up Perjeta (pertuzumab) already
Daiichi-Sankyo takes rival to Roche’s Kadcyla into phase 3

mate Perjeta (pertuzumab).
Daily Brief: Biosimilar Herceptin can't make Perjeta cost effective and more

Herceptin biosimilars can’t make Perjeta cost effective, says NICE. NICE has once again rejected Roche’s HER2-positive breast cancer drug Perjeta for treating patients after surgery in those who ... NICE already recommends Perjeta with trastuzumab
Daily Brief: Theresa May and the diabetes sensor, Biosimilars hit Roche in Europe, Gilead CEO to step down

Perjeta sales continued to grow, specifically in the metastatic and neoadjuvant settings, rising to 1.3bn swiss francs in global sales.
CHMP backs first-line use for AZ’s Tagrisso in lung cancer

Roche picked up an important new approval recommendation for its HER2-targeting drug Perjeta (pertuzumab) as an adjuvant (post-surgery) treatment for HER2-positive breast cancer at high risk of recurrence ... The FDA approved adjuvant use of Perjeta last

More from news
Approximately 17 fully matching, plus 46 partially matching documents found.

Latest Intelligence

Back to the future

In 2013, Roche's biologics sales totalled $29.2bn. These were led by established oncology brands such as Avastin and MabThera/Rituxan, along with emerging breast cancer therapies such as Perjeta

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Programme Director, Healthcare PR, Highly competitive package: Highly Competitive package

Chief Medical Writer, Medical Communications, London, up to £90K...: up to £90K

Senior Medical Writer: Competitive Salary

Account Director: £48, 000 - £60, 000

Account Manager, Healthcare Public Affairs: £32, 000 – £40, 000 benefits

Account Manager, Healthcare Communications: £32, 000 - £40, 000 bonus benefits

Medical/ Scientific Director: Salary TBC

Senior Systematic Review Analyst - Oxford: Negotiable

Digital Manager, London – Healthcare Brandcomms, Medcomms, PR: Excellent package

Medical Writers: Competitive Salary and Benefits

Project / Account Manager (Medical Education): Salary TBC

Leadership opportunity, Pricing & Market Access, UK, Substan...: Substantial six figure package

Account Director: Excellent benefits

Events Manager – Med Comms – Surrey: Salary TBC

Director, Market Access / HEOR - North-West: Negotiable

Senior Account Executive, London, Medical Communications: Excellent package

SAM – Health Behaviour/ Patient Adherence Healthcare Agency: Salary TBC

Associate Director: £75, 000-90, 000

Account Manager, Healthcare Communications: £32, 000 - £40, 000 bonus benefits

Senior Account Director development role to Business Director, H...: Excellent package

Senior Medical Writer (Remote Working): Competitive Salary Offered

Senior Account Manager: Negotiable

Medical Writers Required – Cheshire: DOE

Senior Medical Writer: Great salary and benefits

Production Manager – Healthcare Communications: DOE

Subscribe to our email news alerts

PMHub

Add my company

GCI Health

GCI Health London is a young, vibrant powerhouse in the European industry with a mission to redefine healthcare communications, starting...

Latest intelligence

Innovation in merger control and the impact on the pharmaceutical sector: Is focusing on pipeline products enough to assess regulatory risks?...
Nudge-nudge, think-think: Chris Ross examines the personal complexities of human behaviour – and explains why fun, emotion and peer endorsement could be key to designing effective behavioural change programmes...
Quality in Care Diabetes 2018: the best in innovative diabetes care: Awards highlight new evidence-based approaches to improving care...